Top View
- Daclizumab (Anti-Tac, Zenapax) in the Treatment of Leukemia/Lymphoma
- Adverse Events/Mode of Action Relationship of Monoclonal Antibodies-Based Therapies: Overview of Marketed Products in the European Union
- Daclizumab (Zinbryta) Reference Number: ERX.SPMN.165 Effective Date: 10/16 Coding Implications Last Review Date: 09/16 Revision Log
- Long Term Follow-Up of Tocilizumab in Refractory and Non-Infectious Uveitic Cystoid Macular Edema
- Tailored Therapy for Severe Asthma Francesco Menzella1*, Mirco Lusuardi2, Carla Galeone1 and Luigi Zucchi1
- INN Working Document 05.179 Update 2011
- Zinbryta, INN-Daclizumab
- Daclizumab (Zinbryta) Reference Number: CP.PHAR.269 Effective Date: 08.01.16 Last Review Date: 05.18 Coding Implications Line of Business: Medicaid Revision Log
- As Treatment for Refractory Acute Graft-Versus-Host Disease
- CDER List of Licensed Biological Products With
- (INN) for Biological and Biotechnological Substances
- Blocking Interleukin-4 Enhances Efficacy of Vaccines for Treatment Of
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Treatment and Unmet Needs in Steroid-Refractory Acute Graft-Versus-Host Disease Florent Malard, Xiao-Jun Huang, Joycelyn Sim
- Antibody Drug Nomenclature: -Umab -Zumab -Ximab
- 4 Chimeric and Humanized Antibodies Have a Longer Circulating Half-Life and Reduced Immunogenicity [Adair, F 2002]. 1.5 Objectiv
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- Anti-IL5 Therapies for Asthma (Review)
- Phase II Multi-Centre, Double-Blind, Randomised Trial of Ustekinumab in Adolescents with New-Onset Type 1 Diabetes
- REALLY ESSENTIAL MEDICAL IMMUNOLOGY Arthur Rabson, Ivan M.Roitt, Peter J
- The Way Forward for the Refractory Asthmatic
- 8/15/2020 Code(S): HCPCS J2323 SUBJECT: Tysabri (Natalizumab)
- A Pilot Study to Investigate Ustekinumab (STELARA®)
- An Overview of Acute Myeloid Leukemia and Cancer Immunology: (I) Concepts and Therapeutic Strategies and (Ii) Repsox As a Candidate Cell-Engineering Tool
- Antibody-Drug Analogues
- Long-Term Follow-Up of Corticosteroid Refractory Acute GVHD Treated with an Inolimomab-Based Algorithm: a Single Center Experience
- The Therapeutic Potential of Anti-CD25 Antibodies
- 0805- Basic-Immunology Kline
- Treatment of Noninfectious Intermediate and Posterior Uveitis with the Humanized Anti-Tac Mab: a Phase I/II Clinical Trial
- Biological Therapy in Severe Asthma: a Gem Or a Jam Hesham Raafat
- Customs Tariff - Schedule Xxi - 1
- Vaccination in Immunocompromised Patients ´Biologicals´
- Actemra Iv (S)
- Bjophthalmol-2020-315935 1045..1051
- Structural Basis of Immunosuppression by the Therapeutic Antibody Daclizumab
- Daclizumab (Anti-CD25) in Multiple Sclerosis
- Anti-Il6-R Tocilizumab in Refractory and Non-Infectious Uveitic Cystoid Macular Edema
- Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
- Therapies for Allergic Inflammation: Refining Strategies to Induce Tolerance
- Efficacy and Safety of Biological Therapy Compared to Synthetic
- Infliximab Combination for the Treatment of Severe Gastrointestinal Acute Gvhd
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- Immunomodulatory Treatment for the Intractable Paediatric Epilepsies Luis E
- Standard Induction with Basiliximab Versus No Induction in Low Immunological Risk Kidney Transplant Recipients
- Basiliximab Vs. Limited-Dose Daclizumab (2 Mg/Kg) Administered in Single Or Two Separated Doses in Kidney Transplantation†
- (INN) for Biological and Biotechnological Substances
- New Medications and FDA Updates 2016
- Thalidomide - Wikipedia, the Free Encyclopedia
- Assessment of the Evolution of Cancer Treatment Therapies
- Tenofovir Alafenamide
- Immunotherapy in Asthma
- Population Pharmacokinetics of the Interleukin-23 Inhibitor
- ZENAPAX (Daclizumab) STERILE CONCENTRATE for INJECTION Rx Only WARNING Only Physicians Experienced in Immunosuppressive Therapy
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- ZINBRYTA (Daclizumab) Injection, for Subcutaneous Use DOSAGE FORMS and STRENGTHS Initial U.S
- Specialty Pipeline Update
- Monoclonal Antibodies in Type 2 Asthma: a Systematic Review and Network Meta- Analysis Ahmed Edris1, Silke De Feyter1,2, Tania Maes2, Guy Joos2 and Lies Lahousse1*
- Pathophysiology, Prevention, and Treatment of Acute Graft-Versus-Host Disease
- Progress in Autoimmune Diseases Research